Patient Square Capital LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Patient Square Capital LP reported 19 stock positions worth $241.7 million. Its top holding was Roivant Sciences (ROIV) at 52.1% of the portfolio, followed by Insmed (INSM, 10.4%) and Liquidia (LQDA, 9.3%). Compared with Q4 2024, it opened 4 new positions, sold out of 5, added to 12 and reduced 1. The biggest buy was Insmed (INSM, shares +8%) and the biggest sale an exit from Intra-Cellular Therapies (ITCI).
- Most Recent 13F
- Q2 2026
- Location
- MENLO PARK, CA
- CIK
- 0001819257
- Portfolio Value
- $241.7M (Q1 2025)
- SEC Filing
- 0000950123-25-005195 ↗ filed May 14, 2025
Holdings Value
Holdings 19 stocks · $241.7M
| ROIV Roivant Sciences Ltd. | 52.09% | 12,480,000 | $125.9M | No change |
| INSM Insmed Inc. | 10.42% | 330,250 | $25.2M | Add +7.5% |
| LQDA Liquidia Corp. | 9.29% | 1,522,452 | $22.5M | Reduce -18.2% |
| EYPT Eyepoint Inc. | 3.32% | 1,481,977 | $8.0M | Add +5.1% |
| OCUL Ocular Therapeutix Inc. | 2.79% | 920,199 | $6.7M | Add +95.4% |
| CGEM Cullinan Therapeutics Inc. | 2.75% | 878,897 | $6.7M | No change |
| NRIX Nurix Therapeutics Inc. | 2.20% | 447,296 | $5.3M | Add +0.2% |
| MIRM Mirum Pharmaceuticals Inc. | 2.17% | 116,362 | $5.2M | Add +79.3% |
| ELVN Enliven Therapeutics Inc. | 2.07% | 253,838 | $5.0M | Add +13.3% |
| SRRK Scholar Rock Holding Corp. | 2.05% | 154,000 | $5.0M | Add +381.3% |
| IRON Disc Medicine Inc. | 1.70% | 83,000 | $4.1M | Add +47.2% |
| AGIO Agios Pharmaceuticals Inc. | 1.69% | 139,732 | $4.1M | Add +14.8% |
| KYMR Kymera Therapeutics Inc. | 1.61% | 142,201 | $3.9M | New |
| PHVS Pharvaris NV | 1.59% | 245,496 | $3.9M | Add +18.3% |
| ALLO Allogene Therapeutics Inc. | 1.43% | 2,368,186 | $3.5M | Add +59.0% |
| BPMC Blueprint Medicines Corp. | 1.41% | 38,500 | $3.4M | New |
| NTLA Intellia Therapeutics Inc. | 0.68% | 232,781 | $1.7M | Add +7.8% |
| SLNO Soleno Therapeutics Inc. | 0.55% | 18,600 | $1.3M | New |
| VYNE THERAPEUTICS INC | 0.17% | 257,033 | $406K | New |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
| INSM Insmed Inc. | Add +7.5% | 10.42% | +2.49 |
| KYMR Kymera Therapeutics Inc. | New | 1.61% | +1.61 |
| SRRK Scholar Rock Holding Corp. | Add +381.3% | 2.05% | +1.53 |
| BPMC Blueprint Medicines Corp. | New | 1.41% | +1.41 |
| OCUL Ocular Therapeutix Inc. | Add +95.4% | 2.79% | +1.29 |
| MIRM Mirum Pharmaceuticals Inc. | Add +79.3% | 2.17% | +1.16 |
| SLNO Soleno Therapeutics Inc. | New | 0.55% | +0.55 |
| IRON Disc Medicine Inc. | Add +47.2% | 1.70% | +0.37 |
| ALLO Allogene Therapeutics Inc. | Add +59.0% | 1.43% | +0.24 |
| AGIO Agios Pharmaceuticals Inc. | Add +14.8% | 1.69% | +0.20 |
| ELVN Enliven Therapeutics Inc. | Add +13.3% | 2.07% | +0.18 |
| VYNE THERAPEUTICS INC | New | 0.17% | +0.17 |
| PHVS Pharvaris NV | Add +18.3% | 1.59% | +0.11 |
| NTLA Intellia Therapeutics Inc. | Add +7.8% | 0.68% | −0.26 |
| EYPT Eyepoint Inc. | Add +5.1% | 3.32% | −0.61 |
| NRIX Nurix Therapeutics Inc. | Add +0.2% | 2.20% | −0.95 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $645.5M | ROIV, RVMD, MIRM, ABVX, ONC |
| Q1 2026 | 29 | $563.6M | ROIV, ARGX, INSM, ONC, COGT |
| Q4 2025 | 28 | $467.1M | ROIV, INSM, MIRM, ARGX, ONC |
| Q3 2025 | 24 | $373.9M | ROIV, INSM, EYPT, ABVX, CDTX |
| Q2 2025 | 19 | $277.4M | ROIV, INSM, ARGX, EYPT, LQDA |
| Q1 2025 | 19 | $241.7M | ROIV, INSM, LQDA, EYPT, OCUL |
| Q4 2024 | 20 | $267.4M | ROIV, LQDA, INSM, CGEM, EYPT |
| Q3 2024 | 11 | $269.4M | ROIV, LQDA, CGEM, INSM, EYPT |
| Q2 2024 | 2 | $215.4M | ROIV, LQDA |
| Q1 2024 | 2 | $234.8M | ROIV, LQDA |